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ABSTRACT
A common feature of all the known cancer genetic
syndromes is that they predispose only to selective
types of malignancy. However, many of the genes
mutated in these syndromes are ubiquitously
expressed, and influence seemingly universal pro-
cesses such as DNA repair or cell cycle control. The
tissue specificity of cancers that arise from malfunc-
tion oftheseapparently universal traitsremainsakey
puzzleincancergenetics.MutationsinDNAmismatch
repair (MMR) genes cause the most common known
cancer genetic syndrome, hereditary non-polyposis
colorectal cancer, and the fundamental biology of
MMRisoneofthemostintensivelystudiedprocesses
in laboratories all around the world. This review uses
MMR as a model system to understand mechanisms
thatmay explainthe selectivedevelopment oftumors
in particular cell types despite the universal nature of
this process. We evaluate recent data giving insights
into the specific tumor types that are attributable to
defective MMR in humans and mice under different
modes of inheritance, and propose models that may
explain the spectrum of cancer types observed.
INTRODUCTION
DNA mismatch repair (MMR) and mechanisms of
cancer prevention
More than 1 billion years old, MMR plays critical roles in the
maintenance of genomic stability in prokaryotes, simple euka-
ryotes and metazoan organisms such as humans and rodents
(1–3). Interest in DNA mismatch repair and its mechanisms of
action exploded in the early 1990s with the observation that
germline mutations in MMR genes cause hereditary non-
polyposis colorectal cancer (HNPCC) (4–7). The biology of
MMR has been extensively characterized in model organisms,
and these studies have given tremendous insights into the
function of speciﬁc proteins in humans. The model organisms
in which MMR has been most extensively studied are Escheri-
chia coli and Saccharomyces cerevisiae. Other systems in
which MMR genes have been rigorously characterized include
Caenorhabditis elegans and Arabidopsis Thaliana. The pre-
cise mechanistic function that each MMR protein performs in
these model organisms, as well as humans and mice, has been
covered in detail in numerous excellent reviews (3,8–15).
Therefore, this subject will be summarized only succinctly
here, focusing on mechanisms most likely to be relevant to
the discussion of tissue speciﬁc carcinogenesis.
Brieﬂy, there are nine mammalian MMR genes (MLH1,
MLH3, PMS1-2 and MSH2-6) (3,8). The MMR proteins inter-
act with each other to create a combinatorial code of com-
plexes that mediate distinct functions. The mammalian E.coli
MutS homologs (MSH proteins) are thought to directly cont-
act double-stranded DNA, scanning along the genomic DNA
for mismatches analogous to a ‘sliding clamp’ until they
encounter a base pair containing a mismatch (16,17). The
MSH proteins interact with multiple proteins including the
mammalian E.coli MutL homologs (MLH) and yeast post-
meiotic segregation (PMS) homolog proteins (which have
signiﬁcant amino acid identify and structural similarity to
the MLH proteins), as well as RPA, EXO1, RFC, possibly
HMGB1, and other less well-characterized proteins [reviews
(3,8) as well as the new primary research papers (18–20)
discuss this topic in excellent detail]. With respect to the
mutator function, the MSH2–MSH6 heterodimer is thought
primarily to repair single-base substitutions and 1 bp
insertion–deletion mutations, while MSH2–MSH3 is thought
primarily to repair 1–4 bp insertion–deletion mutations (3,8).
The E.coli MutL homologs (MLH) and yeast PMS proteins
interact with heterodimers of MSH proteins to help catalyze
their different functions. MLH1–PMS2 is the primary MutL
complex that interacts with both MSH2/6 and MSH3
complexes in mechanisms thought to be relevant to cancer
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ory, suggest mammalian MLH1–MLH3 also contributes to
some of these processes as well, but in all mechanisms tested
to a lesser degree than MLH1–PMS2 (21–24). MLH1–PMS1
clearly exists inmammaliancellsbutitcurrentlyhasnoclearly
deﬁned role in processes relevant to cancer susceptibility
(25,26). MSH4 and MSH5 are thought to play roles exclusively
in meiosis and are currently not thought to contribute to mech-
anisms of cancer prevention (27).
A mutator phenotype causing increased mutation rates for
single-base substitution and insertion/deletion mismatches
have traditionally been thought to be the main functions in
MMR cancer prevention. Defects in the insertion/deletion
repair function create a phenotype that is largely thought to
be unique to MMR. Since this function was originally char-
acterized on short repetitive DNA microsatellite sequences,
it is often referred to as Microsatellite Instability or MSI
(28–30). MSI is divided into MSI-Low and MSI-High
(MSI-H) subtypes depending on the percentage of microsatel-
litemarkersthataremutated, butonlythe MSI-High subtypeis
clearly associated with defective MMR. Tumors with no MSI
are referred to as Microsatellite Stable (MSS). [Consensus
thinking on the topic of MSI was recently covered in detail
by Umar et al. (31)]. The precise mechanisms whereby MSI
causes cancer are hypothesized to include a genome wide
increased mutation rate that causes mutations not only in
microsatellites, but also in exonic coding sequences of
genes important in cancer suppression. MSI mutation rates
in these short repetitive sequences in MLH1-o rMSH2-
deﬁcient cells are estimated to be more than 100 times
higher than that seen in MMR-proﬁcient cells and used to
test directly whether MMR deﬁciency is involved in speciﬁc
tumor types. Almost all described MLH1/MSH2 mutations
cause MSI-H tumors, although recently MSS MLH1 non-
synonymous amino acid substitutions causing deleterious
mutations have been described (32,33). Current thinking is
that MMR mutations are recessive (i.e. require two hits
under the Knudson hypothesis) before cells become suscept-
ible to cancer. However, it has been suggested that cells from
subjects carrying heterozygous germline mutations may have
detectable MSI using a more sensitive assay referred to as
single-molecule or small pool PCR (34,35) that can detect
approximately 5- to 10-fold elevations in MSI rates. These
new ﬁndings are intriguing, but require further investigation
before the role of MMR haploinsufﬁciency in cancer suscept-
ibility is clearly established.
In addition to its essential roles in insertion/deletion and
single-base substitution repair, MMR proteins also participate
in additional mechanisms that could contribute to carcino-
genesis, most notably initiation of apoptosis in response to
DNA damage (16,36). Recent studies using mouse models
of single-amino acid substitutions causing separation of
function mutations have demonstrated clearly that decreased
apoptosisplaysanimportant roleinMMR-deﬁcienttumorgen-
esis (37,38). The precise mechanism by which MMR
contributes to the initiation of programmed cell death remains
unclear, with both futile cycles of repair causing high levels of
double-strand breaks and direct signaling proposed (39,40).
MMR mutant cells fail to activate a p73-dependent cell
death activation pathway (41), which may explain the
absence of a critical requirement for p53-mediated apoptosis
(42). This failure impairs cell cycle and DNA damage check-
point recognition (3).
In summary, the current models suggest that MMR muta-
tions cause cancer primarily through the contribution of both
mechanisms: (i) cells acquire mutations in components of
critical tumor suppressor gene pathways that allow them to
proliferate and (ii) cells do not initiate apoptosis appropriately.
It is unclear at present whether these mechanisms operate
sequentially or concurrently in different cell types. MMR pro-
teins also contribute to suppress homeologous recombination
(39,43), which could in principle contribute as an important
mechanism of carcinogenesis. However, the contribution of
increased rates of homeologous recombination from MMR
mutations to carcinogenesis is not well deﬁned at this point
in time.
The spectrum of cancer susceptibility attributable to
MMR deficiency
Mutations in the MMR genes MLH1 and MSH2 were ﬁrst
identiﬁed because of their association with colorectal cancer
in HNPCC families (4–7). Approximately 70–85% of HNPCC
families have identiﬁable mutations in these two genes (9).
Subsequently, HNPCC families with reduced penetrance and
identiﬁable MSH6 and PMS2 mutations were identiﬁed
(44,45). Further studies demonstrated that somatically
acquired defects in MMR mutations are attributable for
 17 000 sporadic colorectal cancer (CRC) (46,47) and
10 000 endometrial cancer (48) new diagnoses in the United
States each year. Germline MSH6 mutations were also shown
to be responsible for an appreciable proportion of familial
colorectal cancer and hereditary uterine cancer families
(49–51). More recently, pediatric patients harboring homo-
zygous recessive MLH1 or MSH2 germline mutations have
also been identiﬁed. In these individuals, the most notable
susceptibility is to hematopoietic malignancies (which are
not generally present in HNPCC) and colorectal cancer
(52–56).
Numerous studies have attempted to characterize the tumor
spectrum and age of onset of HNPCC-related tumors in
affected individuals, but these studies have been fraught
with challenges given the relative rarity of the syndrome
and difﬁculty in gathering prospective data. Most studies
have focused on identifying high-risk families of those that
meet clinical criteria for HNPCC and comparing incidence
data with that of the general population. However, this
approach leads to biases in the data toward higher than actual
rates of tumor development since the most strongly affected
families tend to be included while those with a less severe
phenotype are less frequently recognized (referral bias).
HNPCC-Lynch Syndrome was originally described as a
familial syndrome manifested by elevated incidence of color-
ectal and endometrial cancer and further studies have related
this to MMR defects as well to numerous other cancer sus-
ceptibilities (4–7). Colorectal cancer has been reported in men
with HNPCC with a cumulative lifetime risk upwards of 74%
(57–59), and standardized incidence ratio of 9.6 (95% CI 7.5–
12.3) in a clinic-based study of individuals with MSI-H tumors
and as low as 2.0 (1.3–2.7) in the same study for population-
based data inMSS individuals(60).Inwomen,the riskof CRC
is lower and lifetime risk of endometrial cancer has been
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from Finland, Holland and the United States. Other studies
have placed the lifetime risks of endometrial cancer as much
higher: 42% for women with a mutation in MLH1, 61% for
MSH2 (58). While the elevated risk for both CRC and endo-
metrial cancer in these patients is undisputed, it soon became
clear upon observing these patients and their families that
cancers at other speciﬁc sites seemed to appear far more fre-
quently than one would see in the general population.
Most reliable studies have relied on the calculation of standard
incidence rates to evaluate these observations, i.e. the ratio
of observed to expected cancer rates compared with
population based information. The ﬁrst study on this subject
demonstrated an elevated SIR for gastric cancer (SIR ¼ 4.1),
hepatobiliary (SIR ¼ 4.9), urologic tract (SIR ¼ 2.5), ovarian
(SIR ¼ 3.6), and small bowel cancer (SIR ¼ 25), as well
and an increased but not statistically signiﬁcant SIR of
1.6 for brain tumors (62) which has not been substantiated
by further studies. Further work in this area has veriﬁed these
results, and has repeatedly shown increased risk of small
bowel, hepatobiliary, gastric, skin keratoacanothoma, ureter/
kidney and ovarian tumors. Anecdotal reports of tumors such
as leukemia, lymphoma, pancreas, larynx and breast tumors
have not been substantiated by larger scale observational
studies (60,63).
Recent large-scale population and clinic-based analyses
have been performed that have less overall bias than single
institution case series (60,64–66). These studies use MSI or
loss of immunohistochemical staining as the screening meth-
odology, and therefore identify both germline and sporadic
MMR defects. In these studies, the greatest cancer susceptib-
ility is manifest as colorectal cancer [odds ratio (OR) 4.3–9.6],
endometrial cancer (OR 3.4–5.4), stomach cancer (OR 3.3–
7.1), kidney (OR 1.8–4.1), ovary (OR 1.6–2.6), small intestine
(OR 3.6–9.7) and ureter (OR 6.8–10.0) (Table 1) (60). Sur-
prisingly, signiﬁcantly lower cancer rates are also observed,
most convincingly and repeatedly seen in prostate, breast and
lung cancers (60,63,67). Environmental factors have also been
demonstrated to play a role in the affecting the tumor
spectrum. Recent data from HNPCC mutation carriers
support the assertion that smoking signiﬁcantly increases
CRC risk in HNPCC mutation carriers (hazard ratio of
1.43, P < 0.04) (68).
The spectrum of cancer susceptibility in germline
homozygous MMR mutation mouse models
Mouse models for all nine MMR genes, as well as numerous
combinationsofthesegenes, have been created andhave given
signiﬁcant insights into the mechanisms and cancer sus-
ceptibility of speciﬁc cell types (25,39,69–77). Msh2
 / 
and Mlh1
 /  mice have a highly penetrant cancer susceptib-
ility, which manifests primary as lymphomas, GI epithelial
adenomas and basal cell carcinomas starting at  6 months
of age (25,39,76,78). Msh6
 /  mice display essentially the
same tumor spectrum, but with the same tumor types appear-
ing around 9–12 months of age (72). Pms2
 /  mice develop
lymphomas and sarcomas but not GI tumors, starting around
9–12 months of age (25,79,80). Mlh3
 /  mice have lower
penetrance GI cancer susceptibility and develop GI cancers
with a mean onset of 12 months of age, as well as lymphomas
and skin cancers (23). Pms1
 / , Msh3
 / , Msh4
 /  and
Msh5
 /  mice have to date demonstrated no clear susceptib-
ility to cancer (25,71,81). In summary, the tissue speciﬁcity of
all MMR mouse knock out models is very similar, but with
varying penetrance. In mice, the main tissues affected are GI
epithelial tumors and mixed B and T cell lineage lymphomas.
It is not well understood at present why endometrial, ovarian
and renal cancers do not occur with appreciable frequency
as they do in humans. It has been speculated that this differ-
ence might reﬂect the shorter lifespan of mice, the lower
penetrance of these other cancer types, differences in hor-
monal exposure of the estrous versus menstrual cycles or
environmental exposures.
Table 1. Standardized incidence ratios (SIRs) of cancer risk by site in population-based and clinic-based ascertainment of MMR defective cancers
Tumor site All MSI-H
SIR (60)
Population-based
SIR (60)
Clinic-based
SIR (60)
Incidence
per 100000 (60)
Clinic-based
SIR (63)
Incidence
per 100000 (63)
Combined incidence
per 100000 (60,63)
Colon 6.1 (5.2–7.2) 4.3 (3.4–5.3) 9.6 (7.5–12.3) 5319 N/A
a
Gastric 4.6 (2.7–6.6) 3.3 (1.4–5.4) 7.1 (3.1–11.7) 614 4 1291 802
Uterus 4.1 (2.9–5.6) 3.4 (1.9–4.8) 5.4 (3.1–7.9) 2440 N/A
a 8049 4020
Kidney 2.6 (1.4–4.0) 1.8 (0.5–3.3) 4.1 (1.5–7.1) 438 3 759 528
Lung 0.3 (0.2–0.5) 0.2 (0.0–0.4) 0.6 (0.2–1.1) 351
Ovary 2.0 (1.0–3.2) 1.6 (0.5–3.1) 2.6 (0.8–5.1) 714 3.5 1974
b 1069
b
Breast 0.5 (0.3–0.7) 0.4 (0.2–0.6) 0.6 (0.3–1.0) 1250 <1
Hematopoietic 0.5 (0.2–0.8) 0.7 (0.2–1.1) 0.3 (0.0–0.7) 321 1
Pancreas 1.7 (0.7–2.8) 2.1 (0.8–3.8) 1.0 (0.0–2.7) 292 1
Prostate 0.3 (0.1–0.5) 0.3 (0.1–0.6) 0.3 (0.0–0.7) 292
Small bowel 7.6 (2.5–13.9) 9.7 (1.9–19.3) 3.6 (0.0–12.0) 175 25 759 338
Cervix 0.3 (0.1–0.5) 0.2 (0.0–0.4) 0.5 (0.0–0.9) 357 1 1063
b 556
b
Bladder 0.4 (0.1–0.9) 0.3 (0.0–0.7) 0.8 (0.0–1.8) 146 1 380 211
Hepatobiliary 2.4 (0.6–5.0) 0.9 (0.0–3.2) 5.3 (0.0–11.7) 117 5 532 232
Ureter 9.0 (2.0–18.3) 10.0 (0.0–22.9) 6.8 (0.0–21.8) 117 22 380 190
Brain 0.7 (0.0–1.7) 0.7 (0.0–1.9) 0.6 (0.0–2.1) 88 1
Head/neck 0.3 (0.0–0.6) 0.4 (0.0–0.9) N/A 88 1
Melanoma 0.3 (0.0–0.4) 0.2 (0.0–0.6) N/A 58
aIn this study, these cancers were used to ascertain high-risk families, therefore an unbiased estimate of incidence cannot be estimated.
bEstimated 50% of patients were female in this study.
Relative risk is presented with 95% confidence intervals in parentheses. Data are compiled from (60,63).
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sequences have higher mutation rates in genes
critical for different cell types
Since different cell types have distinct critical tumor sup-
pressor and tumor promoter gene requirements, the precise
sequences of these genes in part may help deﬁne the tissue
speciﬁcity of MMR defects as mutation targets. It is well
appreciated that different cell types have distinct patterns of
gene expression/splicing (82,83) and are dependent on distinct
tumor suppressor and tumor promoter genes [for recent
review, see (84)]. Therefore, it is not surprising to accept
the premise that speciﬁc cell types are more susceptible to
perturbations in speciﬁc signaling pathways than others. It is
clear that defective MMR preferentially causes speciﬁc
sequences to mutate at faster rates than other sequences.
The best-characterized highly speciﬁc preference is for muta-
tion of short pair repetitive sequences, a phenomenon origin-
ally described by Perucho, Shibata, Thibodeau and colleagues
(28,29). Current thinking is that insertion/deletion mutations
of most non-coding genomic microsatellites do not contribute
directly to cancer susceptibility, but that these mutations do
play a role when they occur in coding or proximal promoter
regulatory sequences. Perhaps the best-characterized target is
the transforming growth factor b type II receptor, which in
humans has a 10 Adenine repeat in its coding region that is
frequently mutated in MSI-H CRC tumors (85). Since TGF
Beta signaling is particularly signiﬁcant for GI epithelial cells,
and repression of this pathway’s signaling is relieved by trans-
forming growth factor beta type II receptor (TGFbR2) adenine
repeat frameshift mutations that occur at high rates in MMR
defective cells, the combination of these two events may
explain in part why GI epithelial cells are preferentially trans-
formed in HNPCC. However, because this 10 adenine coding
repeat is not present in mouse Tgfbr2 and the MMR knockout
models develop GI carcinomas, it cannot be the only explana-
tion for the preference of tumors to develop from this cell type.
Recent genome wide surveys have cataloged genes whose
coding sequence contains repetitive mono- and dinucleotide
repeat sequences (86–88) that are likely candidates for frame-
shift mutations in MMR-deﬁcient cells. Because nonsense-
mediated decay (NMD) causes the degradation of many
mRNAs with frameshift mutations causing premature stop
codons, cross comparisons of different gene expression pat-
terns in MSI-H cancers versus normal mucosa with the list of
genes encoding longer repetitive mono- and dinucleotide
repeat sequences are a well focused strategy to identify select-
ive targets in different tissues that explain the predilection of
MMR defects to cause speciﬁc cancer types. Experiments in
cell lines using this approach and selective stabilization of
NMD targeted mRNA transcripts with chemical or genetic
approaches has suggested UVRAG, p300 and GRK as potential
important targetsinMSI-HCRCs (89,90).Itwillbeinteresting
to see how the targets identiﬁed by this approach when tested
in other cell types such as uterine epithelial cells, or use pri-
mary cancer cells.
There is also evidence that even mildly repetitive sequences
in genes whose function is critical are selected with higher
frequency by MMR deﬁciency as common mutation targets.
Forexample,thespectrumofApcmutationsinMMR-deﬁcient
tumors has been exhaustively characterized in mouse models.
In mouse GI epithelial tumors, Apc deletions of a single ‘CA’
in TCC CAC ACA CA or a single ‘GA’ in AAG AGA GAG
AG, both of which are in the Apc coding region, cause frame-
shift truncation mutations have each been observed more than
20 times and occur signiﬁcantly more frequently than any
base-substitution mutation (91–93). Similar observations
have been made in human MSI-H colorectal tumors (94).
Therefore, the contribution of the MMR mutator function to
cancer cell type speciﬁcity is likely to involve elements of
(i) the presence of repetitive coding sequences in speciﬁc
genes, (ii) the expression pattern of those genes and
(iii) the functional importance of those genes so that even
rare mutations can be selected for if they confer a proliferative
advantage.
How do targets of the MMR mutator phenotype
influence tumor specificity?
The observation that human and mouse null mutations for
critical MMR genes allow essentially normal development
demonstrate clearly that the loss of MMR alone is insufﬁcient
to initiation a carcinogenic transforming event, but that addi-
tional genetic changes are also required for the transition to
frank malignancy. The genes that are inactivated by frameshift
mutations in MMR-deﬁcient cancers have been evaluated by
several groups (95,96). Of all the genes, TGFBR2, BAX and
CASP-5 stand out as the most consistently mutated in MMR
defective tissues (95,96). TGFBR2 is consistently mutated in
most MSI-H cell lines and CRC tumors with 1 or 2 bp dele-
tions ina coding poly(A)10 tract causing a frameshiftmutation
(85) and this ﬁnding has been consistently replicated by mul-
tiple groups (95–97). Subsequently, multiple other genes with
putative tumor suppressor functions and containing coding
microsatellites have shown to be mutated at various frequen-
cies in sporadic MSI-H and HNPCC associated colorectal,
gastric and endometrial cancers. These include additional
genes such as IGFIIR, PTEN (98) involved in signal transduc-
tion, apoptosis (BAX, Caspase 5) (95,99), DNA repair, MSH3,
MSH6, MBD4 (100,101), as well as genes that play roles in
transcriptional regulation, protein stability and immune sur-
veillance. It is thought that by analyzing different cell
lines, coding repetitive sequences that are not under growth
selection (found in either tissue or temporally-speciﬁc non-
transcriptionally active genes) or which are essential to cell
survival would only appear with a low frequency proportional
to that of the mutation rate of the MMR-deﬁcient cells. These
genes are sometimes referred to as ‘bystander’ or ‘survivor’
genes’ (102). One would expect a bias toward decreased muta-
tion frequencies in these coding MS (cMS). Finally, that genes
in which frameshift mutations would convey a growth or
selective advantage to the cell, presumably by abrogation of
some tumor suppressor function, can be identiﬁed by a higher
than expect frequency of mutation in MSI-H tumors. Duval
et al. (103) used the maximum likelihood statistical analysis to
search for new genes in which coding repetitive sequence
mutations would provide a selective advantage to growth or
tumor progression in a group of 9 known target genes and 19
others with an expected role in carcinogenesis. They also
analyzed a series of 22 non-coding versus 25 coding short
mononucleotide repeats (<10 bp) where 7/25 coding repeats
(in CASP5, MSH6, IGFIIR, GRB14, BAX, TCF-4 and
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however, a great amount of variability was seen with mutation
frequencies ranging from 2 to 92% in coding, and 0 to 40% in
non-coding sequences (104). Other approaches have (102)
used comprehensive literature search to identify 169 coding
and 25 non-coding repeat sequences in colon, gastric and
endometrial cancer and a cumulative mutation model to pre-
dict the genes with the strongest evidence for involvement in
MMR defective mechanisms of carcinogenesis in the colon.
These genes included TGFb2R, BAX, TCF-4, MSH3, ACVR2,
PTHL3, HT001, AC1, SLC23A1 MACS, NDUFC2 and TAF1B
(88,102). Two other genes, WAF1 and BCL2, were found with
mutation frequencies below the lower prediction limit arguing
for negative selection in these cases. If this prediction is cor-
rect, it could be tested by creating models of MMR deﬁciency
combined with Waf1 or Bcl2 null mice. It follows that obser-
vation of decreased tumor incidence or a shift in tumor spec-
trum would provide further evidence for a negative selection
bias against these cMS. Similar techniques have also been
used to discern a temporal relationship between target
genes in the progression from adenoma to full blown malig-
nancy emphasizing the likelihood that loss of BAX, TGFb2R,
MACS, NDUFC2, and TAF1B as early events and potential
therapeutic targets (88).
Multiple studies have continued to identify a small subset
of genes with coding repetitive sequences whose loss of func-
tion mutations likely contribute to tissue speciﬁcity of
carcinogenesis. More problematic, has been the question of
tissue speciﬁcity of these genes and pathways since there are
obvious differences in target genes according to tissue type.
This has been most frequently studied with regard to attempts
to distinguish genes speciﬁc for either colorectum stomach or
endometrium carcinomas. The spectrum of target genes in
colon and gastric cancers appears very similar (97,105)
with the exception of two genes, TGFb2R (P ¼ 0.0004)
and MSH6 (P < 0.0001). Overall, endometrial cancers
showed far less instability with mutation frequencies of
TGFb2R, MSH6 and MSH3 were signiﬁcantly lower than in
gastrointestinal than endometrial tumors (P < 0.01). As pre-
dicted, in all three cancer types the distribution of mutation
frequencies in putative target genes was bimodal suggesting
a peak for genuine target genes and ‘bystanders’ at lower
frequencies (102).
Why GI epithelial cells and where along the
proximal-distal axis?
Because mutation rates are signiﬁcantly higher in MMR
defective versus proﬁcient cells, current thinking is that the
cell types with the highest overall proliferation rate (and there-
fore the total number of genomic replication cycles) would be
most susceptible to cancer susceptibility attributable from the
MMR mutator phenotype (3,101,106,107). This observation is
likely to contribute to the spectrum of MMR cancers. In
humans, the GI epithelium has the highest known proliferation
rate of all cell types that have been measured and is thought to
turnover approximately every 3–5 days (108).Other cell types
that cycle rapidly include bone marrow, skin and epithelial
cells of the upper GI tract. The in vivo ‘experiment’ of which
cells have the most rapid proliferation rate is repeated daily in
patients with cancer who are treated with standard cytotoxic
chemotherapy agents. These drugs target universal processes
in proliferation such as genome replication by DNA poly-
merases or unwinding by topoisomerases and kill the cells
with the highest proliferation rates. Acutely, patients develop
diarrhea, which reﬂects cell death of lower GI epithelium. In
the next few days later, red, white and platelet blood cells
nadir, hair falls out, and mucositis develops reﬂecting the
slightly less rapid turnover rates of bone marrow progenitor,
hair/skin and upper GI epithelial cells. It is likely that these
high proliferation rates explain in part the high rates of lower
GI epithelial tumors that results from MMR mutations,
although there is a paucity of direct experimental evidence
to support the assertion. However, it is clear that ranking cell
types by proliferation rates alone does not explain why other
tissues, such as the genitourinary tract or ovarian epithelium,
are affected. Therefore, additional causes must exist as well.
MMR-environment interactions in the gastrointestinal
and genitourinary epithelium
MSH2–MSH6 can speciﬁcally recognize distinct types of
damaged DNA (such as those caused by oxidative or alkylat-
ing agents). It has previously been proposed that the tissues
susceptible to malignancy in the context of defective MMR
could be explained by a speciﬁc type of DNA damage occur-
ring primarily at these sites (16). The affected cells would not
correctly initiate apoptosis to this damage, thereby leading to a
selective advantage and transformation (16,109–111). While a
speciﬁc type of DNA damage has not to date been shown to be
unique to the cell types affected by MMR deﬁciency (and
absent in the unaffected cell types), environmental insults
have been demonstrated to play a role in the affecting the
tumor spectrum in both patients and mouse models. Recent
data from HNPCC mutation carriers support the assertion that
smoking signiﬁcantly increases CRC risk in HNPCC mutation
carriers (hazard ratio of 1.43, P < 0.04) (68). Ethnic back-
ground also affects tumor spectrum (112–114), and marked
inter-family variation in risk of HNPCC spectrum cancer is
clearly documented (58,67,115–120). The variance is signi-
ﬁcant in the expressivity of the syndrome (i.e. the distribution
of different tumor types that develops in different HNPCC
families) (115). However, the precise environmental (or
other genetic) modiﬁers that inﬂuence these phenotypic vari-
ances are incompletely characterized.
It is notable that changes in relative tumor susceptibility of
the stomach, small intestine and colorectum are observed to
vary with both the temporal era as well as geography. The ﬁrst
HNPCC family identiﬁed was described by Aldred Warthin,
a pathologist in 1913, in Europe and is referred to as Family G
(121,122). Members of the original family are still alive
today, and descendents have been followed in Europe and
the United States. Similarly, many other HNPCC kindreds
have family histories that extend over a century (48,122).
In the early 20th century, the GI tumors in Family G and
other similar kindreds were distinguished largely by an excess
of stomach adenocarcinoma (123). In mid and late 20th and
early 21st centuries, the GI cancer susceptibility has shifted
to include mostly colorectal cancers. There are also notable
differences between the cancer spectrum of HNPCC families
that have been identiﬁed in Asia, Europe, Australia, North
and South America and Africa. For example, it is of note
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has greater incidence of stomach cancer compared to North
America, South America and Europe, where colorectal cancer
predominates (118,119,122). It has been speculated that the
shift in the GI cancer susceptibility rostral-caudal axis has
reﬂected changes in food preparation and content. In particu-
lar, the decreased use of ‘smoked’ and cured meats resulting
from refrigeration, and the high fat content of the modern
European–American diet have been proposed as important
factors (122). The smoking process of meats is thought to
introduce heterocyclic amine byproducts in the food, and
the curing process involved nitrate salts that cause nitroso-
compounds, which are thought to act as potential mutagens.
Epidemiologic and animal model studies provide evidence for
this model (68,124). Direct experimental evidence supports
the epidemiologic hypothesis that speciﬁc environmental
mutagens play important roles. Cell culture experiments
using Msh2
+/  cells in culture demonstrate that treatments
with the genotoxic agents such as alkylators (ethylnitrosourea)
or DNA cross-likers (mitomycin C) selects for Msh2
 /  cells
that increase in relation to the number of Msh2
+/  heterozyg-
ous cells (125). Part of this selection may reﬂect the observa-
tion thatMMR cells appeartohave higher overall proliferation
rates compared to MMR-deﬁcient cells, which would give
them a growth advantage.
In MMR mouse models, the relative susceptibility of GI
epithelium along the rostral-caudal axis (stomach, small bowel
and colorectum) to form tumors is modulated by dietary fat
and pharmaceuticals. Diets that are high in fat and low in
calcium and folate (commonly referred to as ‘Western
Diets’) increase most signiﬁcantly the incidence of colorectal
tumors compared with small intestine or stomach tumors
(126), which parallels the higher colorectal cancer rates
observed in HNPCC families in North America and Europe.
Non-steroidal anti-inﬂammatory agents (NSAIDs) and PPAR
gamma agonists can decrease small intestine tumors, while
increasing stomach and colon tumors in MMR-deﬁcient
mouse models (127,128). Two randomized prospective
human chemoprevention trials involving NSAIDs and
HNPCC family members are ongoing, and more precise
data as to how well the mouse model ﬁndings can be extended
tohumans willbeavailableinthe next several years(129,130).
CDX2 is a transcription fact that helps specify GI epithelial
cell fate through a rostral-caudal expression gradient. Muta-
tions in Cdx2 are implicated with carcinogenesis in GI epi-
thelium (131,132). As CDX2 down-regulation is frequently
observed in colorectal cancer and mutations and lower expres-
sion are strongly associated with MSI-H CRCs (133), it would
be interesting to test directly, perhaps using mouse models,
whether dietary modulation of Cdx2 function might be an
important mechanism that underlies the shifts along the dif-
ferent epithelia along the lower GI tract for MMR defective
tumors.
While no precise environmental exposures or dietary or
pharmaceutical agents have been speciﬁcally implicated in
the non-GI MMR tumor spectrum sites, it is proposed that
such agents concentrated in the urine may contribute to the
higher rates of renal and ureteral cancers seen in HNPCC
(134). Since cadmium is associated with both inactivation
of MMR (135) and sporadic renal carcinoma (RR 2.0)
(136,137), testing the hypothesis that this agent induces
MMR-deﬁcient renal cancers could be carried out by exposing
MMR defective animal models, or measurements of this ele-
ment in renal tissues from affected patients as cadmium should
not be affected by formalin ﬁxation. Other potential agents to
test prospectively in these models associated with renal cell
cancer risk include asbestos, trichloroethylene and other pet-
roleum by-products that are concentrated in urine.
Target genes in tumors from germline recessive versus
sporadically acquired MMR deficiency
Patients with germline recessive MMR mutations (two mutant
alleles) have a different spectrum of tumor types that that
develops with dominant MMR (one mutant germline allele
and somatic loss of the second allele, or sporadic functional
loss of both alleles). Compared with HNPCC, recessive
MLH1, MSH2, MSH6 and PMS2 mutations cause GI epithelial
cancers as well as acute and chronic myeloid leukemias, Non-
Hodgkin’s lymphomas, dermal neuroﬁbromas characteristic
of Neuroﬁbromatosis Type I and perhaps glioblastomas
(52–56,138).
The observation that the cancer susceptibility of recessive
versus dominant MMR mutations is different may give clues
as to potential target genes. In particular, the leukemia sus-
ceptibility ofpatientswith germline recessive MMR mutations
suggests an interesting experimental model. This model would
predict that there exists a primitive myeloid progenitor cell
type during early development (i.e. present in individuals who
inherit two MMR mutant alleles) not present in adults (such as
in patients who inherit one mutant allele and have somatic loss
of the second allele) that contains (i) target genes particularly
sensitive to MMR-deﬁcient mutation, or (ii) critical depend-
ence on MMR mediated apoptosis. Furthermore, this model
would also predict that this primitive myeloid progenitor cell
type is rare or absent during adult life, and therefore not sus-
ceptible to transformation by dominant MMR mutations with
subsequent loss of the second allele. In support of the ﬁrst
prediction by this model, mechanistic studies in mouse models
looked at MMR germline defects combined with mice that are
mutant for Nf1, the gene mutated in Neuroﬁbromatosis Type I.
Mlh1
 / ;Nf1
+/  mice develop myeloid leukemias, similar to
the hematopoietic malignancies observed in patients with
recessive MMR mutations (139). The tumors had signiﬁcant
MSI-H mutations, and loss of neuroﬁbromin expression in all
tumors analyzed. These results suggest that MMR deﬁciency
can accelerate myeloid leukemogenesis in Nf1
+/  mice, pre-
sumably by inactivating Nf1 gene expression as a myeloid
lineage tumor suppressor gene. As there is substantial evid-
ence that inherited versus sporadically acquired mutations
signiﬁcantly inﬂuence the types of tumors that develop
[reviewed in (140)], and all the current described MMR
mouse models use germline mutations, future experiments
involving inducible Mlh1 or Msh2 mutations using Cre-Lox
technology in ovary, kidney or uterus will be important to test
whether these models develop cancers in those tissues.
Immune surveillance and tissue specificity of
cancer susceptibility
The insertion/deletion frameshift mutation phenotype of
MMR deﬁciency is predicted not only to cause gene muta-
tions, but also lead to the creation of novel protein antigens
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expressed in cells. It has been suggested that additional
tumor types may develop in MMR null patients, but that
they are suppressed by the immune system. In support of
this concept, MSI-H CRCs are associated with a higher con-
centration of inﬁltratinglymphocytes than are MSSCRCs, and
this pathological ﬁnding is included as one of the features to
help physicians screen for MSI-H tumors (141).
Because MMR null mouse models develop NHL while
HNPCC patients generally do not, a recent study screened a
large series human NHLs for MSI. The MSI-H phenotype was
present only in patients with HIV or iatrogenic (post bone
marrow transplant) induced immunodeﬁciency (142). These
data are consistent with a model whereby helper T-cell medi-
ated immune surveillance does play a role in suppressing
NHLs that develop in the context of MMR deﬁciency (pre-
sumably in these cases due to homozygous somatic inactiva-
tion), and thereby contributes to limiting the clinically
apparent cancers in patients. The observation is supported
by mouse model studies that show combining MMR deﬁ-
ciency with immunodeﬁciency (Msh2
 / ;Foxn1
 /  and
Msh6
 / ;Foxn1
 / ) signiﬁcantly increases NHL susceptibil-
ity (143). Why immunocompetant MMR homozygous mutant
pediatric patients and mouse models develop NHLs is unclear,
but the parallel ﬁndings suggest the same mutator or anti-
apoptotic targets may be affected in both species. The iden-
tiﬁcation of frameshift-inactivating mutations of pro-apoptotic
factors BAX and Caspase-5 in the NHLs from immunodeﬁ-
cient patients predicts they may be affected in the mouse
models. However, since mouse Bax lacks the polyguanine
repeat present in human BAX and the mouse ortholog of
Casp5 is controversial, these experiments would require
‘humanizing’ these genes in mice before analyzing mouse
lymphomagenesis.
Tissue specificity of apoptosis mechanisms in
MMR defective cancers
Failure of apoptosis is considered to be one of the six funda-
mental hallmarks of malignant disease (144) and clearly plays
a major physiologic role in MMR-deﬁcient tumors (145,146).
These observations provide a preliminary basis for the exam-
ination of the role of apoptosis in MMR defective cell type
speciﬁc cancer susceptibility. There are three reasons for
thinking that initiation of apoptosis may contribute to MMR
defective tumor speciﬁcity. First, current quantitative biolo-
gical models of colorectal cancer emphasize abrogation of
apoptosis as a very early stage in progression (147,148).
These integrative biology models provide evidence that
defects in apoptosis precede increases in mutation rates or
genomic instability, which are thought to affect progression.
Second, different cell types have distinct critical requirement
for different genes in apoptotic signal transduction pathways.
These cell type speciﬁc requirements have been characterized
in different tissues, with the best-characterized example the
somatic selection for BCL2 expression in B-cell lymphomas
(149). Other mutations in apoptotic genes, in contrast, are
critical for other cell types. For example, Caspase-9, Cyto-
chrome C and Bax models demonstrate critical roles for these
genes in neural apoptosis, while caspase-8 and FADD are
critical in cardiomyocyte apoptosis (150). In wild-type and
MMR defective cells, there is preliminary evidence that
apoptosis may be mediated through a PARP-1 dependent
but caspase independent mechanism (93,151). Since there
exist selective blockers of PARP-1 (DHIQ and DPQ) and
caspase inhibitors (BAF and Z-VAD.fmk), studies to invest-
igate the precise contribution of these different apoptotic
pathways in different cell types that are either susceptible
or resistant to MMR defective carcinogenesis may be inform-
ative whether critical signaling defects correlate with cell
types susceptible to defective MMR-induced carcinogenesis.
It is notable that BAX, which helps mediate Caspase-3 indu-
cible apoptosis, is a common target of MMR mutations. It is
underappreciated that mathematical and computer models of
multistage theories of progression can be used to predict can-
cer rates in different cell types from quantitative aspects of
apoptosis andDNA repair (152). Ifprecise quantitative data on
cell proliferation and mouse model tumor incidence data can
be collected from tissues that are susceptible and resistant to
MMR defective carcinogenesis (colorectal and breast epithe-
lium for example), speciﬁc predictions of the relative contri-
butions of apoptosis can be used to predict which additional
tumor types would be susceptible to MMR inactivation by
using age-speciﬁc penetrance, stage and metachronicity para-
meters. Third, apoptosis is particularly critical for all the cell
types that are susceptible to cell autonomous MMR deﬁciency,
including gastrointestinal, ovarian and endometrial epithelium
and white blood cells. As discussed, many of the most crucial
membersofapoptoticpathwaysfortheseorgansitescanbetar-
geted MMR-deﬁcient mutation, most notably BAX, APAF-1,
BCL10, CASP-5, FAS and others (105).
In particular, the role that apoptosis plays in uterine endo-
metrium and ovarian epithelium as part of normal tissue
physiology is underappreciated. In response to hormonal
stimulation, the uterine endometrium undergoes monthly cyc-
ling including a proliferative or follicular (pre-ovulatory),
secretory orluteal (post-ovulatory)and menstrual phases.Dur-
ing each of these phases, there is marked change in the quant-
ity of and quality of the endometrial cells. The proliferative
phase is marked by high mitotic index, and Ki-67 indicative of
rapid cellular proliferation, as well as elevated levels of BCL2,
ananti-apoptoticfactor,presumably involvedinstabilizing the
cells during this period and allowing for normal physiologic
growth in preparation for implantation and pregnancy (153).
During the luteal phase, BCL2 expression falls,consistent with
the appearance of apoptotic cells, and with higher expression
of Fas, Fas-L and elevated activity of caspases 3, 8 and 9 from
the luteal phase to menstruation (154). These cycle-related
changes in expression are most prominent in the glandular
epithelial cells where menstrual-related endometrial thicken-
ing and sloughing occurs, as well as the most common site of
endometrial carcinogenesis in MMR deﬁciency. More consist-
ent basal levels of BCL2 expression are maintained in basal
laminal, stromaland epithelialcells, whereescapeof apoptotic
death is necessary for these cells to rebuild the functional
endometrium with the next hormonal cycle. Similar studies
in the ovary demonstrate the importance of programmed cell
death in this organ. During the menstrual cycle, a single
maturefollicleisreleasedbyruptureoftheovarian epithelium.
Multiple studies have implicated apoptosis and related signal-
ing pathways as the mechanism of ovarian cell death
(155,156). BCL2 expression is markedly elevated during the
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regressing corpus luteum (157).Assays of DNA fragmentation
as a marker for apoptotic cell death showed high molecular
weight DNA during early luteal phases, while mid-luteal
phase DNA demonstrates cleavage into low molecular weight
ladders (158).
The critical role of apoptosis in the susceptibility of ureter
and urologic system, however, is less clear. Urothelial cells
have a relatively low basal rate of proliferation and apoptosis
in order to maintain tissue homeostasis (159); there is some
evidence that this rate changes over time with exposure to
toxins and other environmental exposures in the urine. This
may also lead to potential apoptotic cell death and entry into
wound healing pathways; however, the evidence for apoptotic
signaling pathways contributing to GU cancers is less clear.
Acceleration and deceleration of proliferation: are the
rates of change of proliferation rates important?
Although less intensively studied than the GI tract, it is
clear that uterine endometrial and ovarian epithelial cancers
are susceptible to defective MMR (Table 1). A study
recently compared on a large-scale GI epithelial and uterine
endometrial cancers as to which MSI susceptible genes
contain frameshift mutations (97). This study suggested that
the proﬁle of target gene mutations demonstrates both
qualitative and quantitative differences between gastroin-
testinal and endometrial MSI-H cancers. For colorectal and
gastric MSI-H tumors, the genes affected were essentially
identical. Mutations in the DNA-dependent protein kinase
catalytic subunit, Glnac, CCAAT-box binding factor and
CtBP-interacting protein coding regions appeared to be
speciﬁc for endometrial but not GI MSI-H tumors (97).
However, they do not clearly establish cell type speciﬁc
GI-uterine targets that would not be expected to play roles
in other tissues as well. In MMR-deﬁcient mouse model
experiments, Pten, a gene mutated also in human MMR
defective cancers (103), was shown to be an important target
whose mutation increases endometrial cancer rates (160).
Since PTEN mutations are implicated in many non-MMR
spectrum malignancies (such as thyroid), other factors must
be included as well to explain why the high penetrance of
endometrial cancer in HNPCC, which in women can exceed
that of CRC (161,162).
What might explain the susceptibility of uterine endomet-
rium and ovarian epithelium? Recently, it has been proposed
that the rate of change of cell proliferation,and not just the rate
of proliferation, may play an important role in tumor initiation
(163), and both these tissues experience hormonally induced
rapid stop/start changes in proliferation rates rather than
gradual changes. The endometrium experiences a monthly
cycle of estrogen and progesterone responsive abrupt rapid
proliferation, followed by abrupt apoptosis and regression.
The ovarian epithelium has a similar monthly cycle of
hormonally induced rupture to release follicles, and then
abrupt rapid proliferation to repair the ruptured epithelium.
In summary, these tissues are characterized not only by
relatively high proliferation rates but particularly by rapid
acceleration and deceleration in the rates of proliferation,
which can be characterized by the ﬁrst derivative of the
cell proliferation velocity.
Itis noteworthythat stomachand colorectum epithelialcells
also are characterized by unusually variable changes in pro-
liferation rate velocity. The classic studies of cell kinetic stud-
ies using thymidine labeling of epithelial cells from human
stomach, small intestine and colorectum both in vivo (164) and
in vitro short term tissue culture (108,165) show similar over-
all rates of proliferation in human small intestine, but signi-
ﬁcantly higher changes in proliferation rate, in human stomach
or colorectum epithelium compared with the small intestine
(108,164,165). Since the penetrance of stomach and colorectal
cancer is consistently much higher than small bowel cancer in
HNPCC regardless of geography or diet, these studies provide
evidence for a potential link between proliferation rate accel-
eration/deceleration and the cell types most susceptible to
MMR defective mechanisms of carcinogenesis. Furthermore,
hematopoietic white blood cell and non-melanotic dermal lin-
eages are susceptible to immunological and (in the latter case)
sunlight induced abrupt cycles of stop/start rapid proliferation.
Based on the available data, we propose a model that the
hormonally induced cycle of monthly rapid acceleration and
deceleration of proliferation rate may play a signiﬁcant role in
uterine endometrial and ovarian epithelial cells to MMR
defective cancer susceptibility. If correct, this model would
suggest several testable features. First, that endometrial/ovar-
iancancersrateswouldbehigherwithinducible rapidburstsof
stop/start proliferation compared to the same number of cell
division cycles induced more gradually. Similarly, the model
would predict that abruptly blocking endometrial/ovarian epi-
thelial cell hormonal dependent proliferation while controlling
for the overall number of cell division cycles would make cells
more susceptible to carcinogenesis. Importantly, the model
would also predict mechanistically that genes critical for ter-
minating the cell cycle and initiating apoptosis or senescence
(stepping on the brakes of proliferation) would be mutated at
higher rates in the tissues with rapid bursts of stop/start pro-
liferation compared to those with high proliferation rates but
more gradual changes in rates (Figure 1).
This model could ﬁrst be tested in synchronized cell culture
directly using MMR defective cell lines, where mutation rates
can be quantiﬁed. If there is a proliferative advantage for
MMR defective cells in an environment of fast acceleration/
deceleration, it would also predict that, analogous to experi-
ments using DNA damaging agents (125), MMR second hit
mutations would be selected for by this treatment. Also, it
could be tested using MMR-deﬁcient mice and tissue speciﬁc
inducible oncogenes such as Myc that are active only in the
presence of speciﬁc ligands.The same modelscould beused to
evaluate the affect of rapid acceleration/deceleration of pro-
liferation in tissues with consistently have lower cancer rates
in MMR defective individuals such as prostate, breast
(60,63,67,117). It is important to note that while hormonally
responsive cycles of stop/start proliferation are also seen in
breast epithelium, it is distinctive from that seen in the endo-
metrium and ovary. The primary rapid proliferative responses
of human breast epithelium are during puberty and pregnancy,
not during menses, while the primary hormonally induced
response during menses is largely hypertrophic, not hyperpro-
liferative (166,167). If correct, our model would predict in
the context of MMR deﬁciency, pulsatile induction of Myc
or other oncogenes would have a much greater affect than
continuous Myc expression.
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The tissue speciﬁcity of cancers that arise from malfunction
of ubiquitously expressed processes such as MMR remains a
key puzzle in cancer genetics. Based on the accumulated
data, we propose there is likely no single mechanism that
can explain fully the cell type speciﬁcity observed in the
spectrum of MMR defective cancers. A more likely explana-
tion is that several distinct mechanisms contribute to shape the
observed tissue speciﬁcity, and contribute in different ways to
different tissues (Figure 2). For the GI epithelium, important
facts include particularly rapid proliferation rates, exposure
to mutagens from the diet, the dependence on critical genes
whose sequences contain short repetitive sequences. For
the endometrium, cell type speciﬁc targets of the mutator
and anti-apoptosis functions of MMR are likely important,
but endometrium speciﬁc targets need to be more precisely
characterized. For the renal tract, concentration of environ-
mental mutagens in the urine are likely important, but these
mutagens need to be studied in more detail. For the ovary, cell
type speciﬁc targets are likely to be important, but they too
need to be understood more clearly. For lymphocytes, both the
mode of inheritance (Germline Recessive versus Somatically
acquired MMR Deﬁciency) and immune surveillance play
important roles. Finally, we propose that not only high pro-
liferation rates, but the rapid acceleration and deceleration of
proliferation rates may play a signiﬁcant role in the speciﬁc
cell types affected by MMR deﬁciency, and suggest experi-
ments to test this hypothesis directly.
Figure 1. Model of cell proliferation at constant and varying rates of cell division. The left panel shows a conceptual model of cells dividing at a constant rate. The
number of cell divisions is plotted on the y-axis and time on the x-axis. The proliferation rate is constant until the tenth cell division, when proliferation stops (as
denoted by a Stop sign). The right panel shows a model of cells dividing at varying rates. There are repeated episodes of sharp acceleration and deceleration (as
denoted by a Stop sign) of the proliferation rate, starting at time point zero. The proliferation rate is constantly changing and is not constant. The potential selective
advantagesforgrowthandincreasedoverallmutationsincriticaltumorsuppressorgenesforcellsexperiencingcyclesofabruptstop/startcelldivisionisdiscussedin
the section ‘ACCELERATION and deceleration of proliferation: are the rates of change of proliferation rates important?’
Figure 2. Summary of different mechanisms contributing to the specificity of cell types that are susceptible to MMR deficiency.
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